| Bram Newman, MD | |
|
49 Spring St, Scarborough, ME 04074-8926 | |
| (207) 885-0011 | |
| Not Available |
| Full Name | Bram Newman |
|---|---|
| Gender | Male |
| Speciality | Sports Medicine |
| Experience | 9 Years |
| Location | 49 Spring St, Scarborough, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952787954 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | MD23423 (Maine) | Secondary |
| 2081S0010X | Physical Medicine & Rehabilitation - Sports Medicine | MD23423 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maine Medical Center | Portland, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Maine Medical Partners | 9335043967 | 789 |
| Mainehealth | 7517860588 | 2067 |
News Archive
A survey of close to 1000 migrants in Mali found that only four had been deceived, exploited, or not paid for their labour. Rather, young people voluntarily sought employment abroad to experience urban lifestyles, learn new languages, and accumulate possessions.
Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition, Weight loss products, and Contract Manufacturing services, and Innovative laboratories, one of the fastest-growing Weight Loss brands in the United States, today announced that they have entered into a definitive agreement in which Hi-Tech has agreed to acquire Innovative's brand of Diet Aids.
Using strong and targeted but noninvasive magnets at specific sites in the brains of people with and without mild learning and memory problems, Johns Hopkins researchers report they were able to detect differences in the concentrations of brain chemicals that transmit messages between neurons.
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
With the onset of COVID-19 in China, the government placed drastic restrictions on travel and work. This action led to a huge reduction in the number of vehicular movements and factories running. Now, a recent study published in the journal Science of The Total Environment in August 2020 shows this change had an unintended benefit – it cleared the air over northern China dramatically.
› Verified 4 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134144090 PECOS PAC ID: 9335043967 Enrollment ID: O20040331000191 |
News Archive
A survey of close to 1000 migrants in Mali found that only four had been deceived, exploited, or not paid for their labour. Rather, young people voluntarily sought employment abroad to experience urban lifestyles, learn new languages, and accumulate possessions.
Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition, Weight loss products, and Contract Manufacturing services, and Innovative laboratories, one of the fastest-growing Weight Loss brands in the United States, today announced that they have entered into a definitive agreement in which Hi-Tech has agreed to acquire Innovative's brand of Diet Aids.
Using strong and targeted but noninvasive magnets at specific sites in the brains of people with and without mild learning and memory problems, Johns Hopkins researchers report they were able to detect differences in the concentrations of brain chemicals that transmit messages between neurons.
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
With the onset of COVID-19 in China, the government placed drastic restrictions on travel and work. This action led to a huge reduction in the number of vehicular movements and factories running. Now, a recent study published in the journal Science of The Total Environment in August 2020 shows this change had an unintended benefit – it cleared the air over northern China dramatically.
› Verified 4 days ago
| Entity Name | Mid Coast Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932164795 PECOS PAC ID: 5496739468 Enrollment ID: O20040623001212 |
News Archive
A survey of close to 1000 migrants in Mali found that only four had been deceived, exploited, or not paid for their labour. Rather, young people voluntarily sought employment abroad to experience urban lifestyles, learn new languages, and accumulate possessions.
Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition, Weight loss products, and Contract Manufacturing services, and Innovative laboratories, one of the fastest-growing Weight Loss brands in the United States, today announced that they have entered into a definitive agreement in which Hi-Tech has agreed to acquire Innovative's brand of Diet Aids.
Using strong and targeted but noninvasive magnets at specific sites in the brains of people with and without mild learning and memory problems, Johns Hopkins researchers report they were able to detect differences in the concentrations of brain chemicals that transmit messages between neurons.
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
With the onset of COVID-19 in China, the government placed drastic restrictions on travel and work. This action led to a huge reduction in the number of vehicular movements and factories running. Now, a recent study published in the journal Science of The Total Environment in August 2020 shows this change had an unintended benefit – it cleared the air over northern China dramatically.
› Verified 4 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
A survey of close to 1000 migrants in Mali found that only four had been deceived, exploited, or not paid for their labour. Rather, young people voluntarily sought employment abroad to experience urban lifestyles, learn new languages, and accumulate possessions.
Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition, Weight loss products, and Contract Manufacturing services, and Innovative laboratories, one of the fastest-growing Weight Loss brands in the United States, today announced that they have entered into a definitive agreement in which Hi-Tech has agreed to acquire Innovative's brand of Diet Aids.
Using strong and targeted but noninvasive magnets at specific sites in the brains of people with and without mild learning and memory problems, Johns Hopkins researchers report they were able to detect differences in the concentrations of brain chemicals that transmit messages between neurons.
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
With the onset of COVID-19 in China, the government placed drastic restrictions on travel and work. This action led to a huge reduction in the number of vehicular movements and factories running. Now, a recent study published in the journal Science of The Total Environment in August 2020 shows this change had an unintended benefit – it cleared the air over northern China dramatically.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bram Newman, MD 49 Spring St, Scarborough, ME 04074-8926 Ph: (207) 885-0011 | Bram Newman, MD 49 Spring St, Scarborough, ME 04074-8926 Ph: (207) 885-0011 |
News Archive
A survey of close to 1000 migrants in Mali found that only four had been deceived, exploited, or not paid for their labour. Rather, young people voluntarily sought employment abroad to experience urban lifestyles, learn new languages, and accumulate possessions.
Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition, Weight loss products, and Contract Manufacturing services, and Innovative laboratories, one of the fastest-growing Weight Loss brands in the United States, today announced that they have entered into a definitive agreement in which Hi-Tech has agreed to acquire Innovative's brand of Diet Aids.
Using strong and targeted but noninvasive magnets at specific sites in the brains of people with and without mild learning and memory problems, Johns Hopkins researchers report they were able to detect differences in the concentrations of brain chemicals that transmit messages between neurons.
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
With the onset of COVID-19 in China, the government placed drastic restrictions on travel and work. This action led to a huge reduction in the number of vehicular movements and factories running. Now, a recent study published in the journal Science of The Total Environment in August 2020 shows this change had an unintended benefit – it cleared the air over northern China dramatically.
› Verified 4 days ago
Michael J Totta, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 49 Spring St, Scarborough, ME 04074 Phone: 207-885-0011 Fax: 207-885-5851 | |
Dr. Alexander John Martinez, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 92 Campus Dr Fl 1, Scarborough, ME 04074 Phone: 207-885-0011 | |
Mr. Vincent Paul Herzog, D.O. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 306 Us Route 1, Scarborough, ME 04074 Phone: 207-883-3434 Fax: 207-883-1424 | |
Stephanie Chan, MD, FAAPMR Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 92 Campus Dr, Scarborough, ME 04074 Phone: 207-885-0011 Fax: 207-661-4501 | |
Dr. Douglas Hunter Buxton, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 49 Spring St, 1st Floor, Scarborough, ME 04074 Phone: 207-885-0011 Fax: 207-885-5851 | |
Angela Mousette, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 67 Pine Point Rd, Scarborough, ME 04074 Phone: 207-299-8594 | |
Dr. John W. Hall, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 49 Spring St, 1st Floor, Scarborough, ME 04074 Phone: 207-885-0011 Fax: 207-885-5851 |